The U.S. launch of a biosimilar to AbbVie’s Humira appears to be hurting the copycat’s developer itself. After AbbVie reported a Humira U.S. sales decline of 26% in the first quarter, Amgen said its ...
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...
Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar versions as part of its Biosimilars Initiative. Alberta, Canada has expanded ...
A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...
(Reuters) - Amgen Inc's version of AbbVie Inc's Humira arthritis drug, the world's top-selling medicine, appears similar in potency and safety to the original product, U.S. Food and Drug ...
Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults. The recommendations also apply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results